IMMUNOLOGICAL CHANGES IN THE INVASION OF HELICOBACTER PYLORI: PROSPECTS FOR CREATING VACCINES
Yu. P. Uspenskiy,
I. A. Gorbacheva,
A. N. Suvorov,
M. M. Galagudza, 
N. V. Baryshnikova,
S. A. Bogdanova
N. V. Baryshnikova,
S. A. Bogdanova https://doi.org/10.18705/2311-4495-2018-5-6-31-40
Abstract
In this article we wrote about main immunologic disorders in Helicobacter pylori infected patients (changes of local, cell and humoral immunity). We have our own data about changes of interleukins 1β, 4 and 8 level in cagA(+) and cagA(−) Helicobacter pylori strains infected patients: we saw that level of proinflammatory interleukin-1β and unterleukin-8 are higher and level of anti-inflammatory interleukin-4 are lower in patients infected cagA(+) strains of Helicobacter pylori. We demonstrated results of different studies about efficacy of anti-Helicobacter pylori vaccines as immunologic prophylaxis of this microorganism invasion: usage of mucosal adjuvants and usage of immunostimulating probiotics during vaccination have promising results.
About the Authors
Yu. P. Uspenskiy
Pediatric Saint Petersburg State Medical University,
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
MD, Doctor of Science, Professor, Head of faculty therapy department named after Valdman Pediatric Saint Petersburg State Medical University, Professor of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University
I. A. Gorbacheva
Pavlov First Saint Petersburg State Medical University
MD, Doctor of Science, Professor, Head of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University
A. N. Suvorov
Science Research Institute
Associate of the Russian Academy of Science, MD, PhD, Professor, Head of Molecular microbiology department of the Institute of Experimental Medicine
M. M. Galagudza
Almazov National Medical Research Centre
Associate of the Russian Academy of Science MD, PhD, Professor, Head of the Institute of Experimental Medicine, Almazov National Medical Research Centre
N. V. Baryshnikova
Pavlov First Saint Petersburg State Medical University,
Science Research Institute
Russian Federation
Russian Federation
MD, PhD, Associate Professor of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University, Science Employer of Molecular microbiology department of the Institute of Experimental Medicine
L’va Tolstogo str., 6/8, Saint Petersburg, Russia, 197022
S. A. Bogdanova
Pavlov First Saint Petersburg State Medical University
Clinical Ordinator of internal diseases department of stomatological faculty of Pavlov First Saint Petersburg State Medical University
References
1. Mayanskiy AN, Mayanskiy DN. Essays on the neutrophil and macrophage. Novosibirsk: izdatel’stvo “Nauka”, 1989. p. 344. In Russian.
2. Novikov DK, Novikova VI. Immune status assessment. M.: Vitebskiy medinstitut, 1996. p. 282. In Russian.
3. Makristathis A, Rokita E, Labigne A. et al. Highly significant role of Helicobacter pylori urease in phagocytosis and production of oxygen metabolites by human granulocytes. J Infect Dis. 1998; 177(3):803–806.
4. Pimanov SI. Esophagitis, gastritis and peptic ulcer: a guide for doctors. N. Novgorod: izdatel’stvo NGMA, 2000. p. 386. In Russian.
5. Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut. 2008;57(5):561–567.
6. Cardoso CR, Teixeira G, Provinciatto PR et al. Modulation of mucosal immunity in a murine model of food-induced intestinal inflammation. Clin Exp Allergy. 2008;38(2):338–349.
7. Chernin VV. Peptic ulcer, chronic gastritis and esophagitis in terms of dysbiosis esophagogastroduodenal area. Еxperimental and clinical gastroenterology. 2006;3:68–69. In Russian.
8. Dubcova EA. Some immunological aspects of ulceration. Experimental and clinical gastroenterology J. 2002; 4: 9–14. In Russian.
9. Uspenskiy YP, Suvorov AN, Baryshnikova NV. Helicobacter pylori infection in clinical practice. SPb.: InformMed, 2011. р. 572. In Russian.
10. Sharma CM, Hoffmann S, Darfeuille F et al. The primary transcriptome of the major human pathogen Helicobacter pylori. Nature. 2010;464(7286):250–255.
11. D’Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter. 2009:14(1): 21–28.
12. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212: 256–271.
13. Aebischer T, Meyer TF, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter. Helicobacter. 2010;15(1):21–28.
14. Kaparakis M, Philpott DJ, Ferrero RL. Mammalian NLR proteins; discriminating foe from friend. Immunol Cell Biol. 2007;85(6):495–502.
15. Amedei A, Cappon A, Codolo G et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 2006;116(4):1092– 1101.
16. Magen E, Mishal J, Schlesinger M et al. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. Helicobacter. 2007;12(5):567–571.
17. Berezhnaya NM, Chehun VF, Sepiashvili RI. Eosinophils, basophils and immunoglobulin E in antitumor protection. Allergology and immunology. 2005;6(1):38–49. In Russian.
18. Maloy KJ. Induction and regulation of inflammatory bowel disease in immunodeficient mice by distinct CD4+ T-cell subsets. Methods Mol Biol. 2007;380:327–335.
19. Lazebnik LB, Chernuckaya SP, Gervazieva VB et al. The role of H. pylori in the development of allergic diseases in patients with lesions of the stomach and duodenum. Therapeutic archive. 2008;80(12):63–66. In Russian.
20. Imamura S, Sugimoto M, Kanemasa K et al. Inverse association between Helicobacter pylori infection and allergic rhinitis in young Japanese. J Gastroenterol Hepatol. 2010;25 (7):1244–1249.
21. Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med. 2007;167(8):821–827.
22. Sokolova NN, Kuzin VB, Dugina VV et al. Study of the effect of Derinat and licopid on the eradication of Helicobacter pylori in patients with chronic ulcer disease of the stomach and duodenum. Medical almanac. 2011;2(15):188–190. In Russian.
23. Tkachenko EI, Uspenskiy YP, Baryshnikova NV. Optimization of treatment of diseases associated with Helicobacter pylori. Doctor. 2012;1:36–38. In Russian.
24. Aebischer T, Schmitt A, Walduck AK et al. Helicobacter pylori vaccine development: facing the challenge. Int J Med Microbiol. 2005;295(5):343–353.
25. Shi T, Liu WZ, Gao F et al. Intranasal CpGoligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter. 2005;10(1):71–79.
26. Baryshnikova NV, Suvorov AN, Tkachenko EI et al. The role of genetic features of Helicobacter pylori in the pathogenesis of diseases of the digestive system: from theory to practice. Experimental and clinical gastroenterology. 2009; 1: 12–19. In Russian.
27. Del Giudice G, Covacci A, Telford JL et al. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol. 2001;19:523–563.
28. Vorobjova T, Watanabe T, Chiba T. Helicobacter pylori immunology and vaccines. Helicobacter. 2008;13(1):18–22.
29. Ferrero RL, Thiberge JM, Kansau I et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA. 1995;92(14):6499–6503.
30. Cuenca R, Blanchard TG, Czinn SJ et al. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology. 1996;110(6):1770–1775.
31. Stadtlander CT, Gangemi JD, Khanolkar SS et al. Immunogenicity and safety of recombinant Helicobacter pylori urease in a nonhuman primate. Dig Dis Sci. 1996;41(9):1853–1862.
32. Michetti P, Corthésy-Theulaz I, Davin C et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology. 1994;107(4):1002–1011.
33. Smythies LE, Novak MJ, Waites KB et al. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine. 2005;23(7):901–909.
34. Todoroki I, Joh T, Watanabe K et al. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun. 2000;277(1):159–163.
35. D’Elios MM, Andersen LP. Helicobacter pylori inflammation, immunity, and vaccines. 2007;12(1):15–19.
36. Nedrud JG, Bagheri N, Schön K et al. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS One. 2013;8(12):e83321.
37. Chionh YT, Arulmuruganar A, Venditti E et al. Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant. Vaccine. 2014;32(20):2350–2358.
38. Sjökvist Ottsjö L, Flach CF, Clements J et al. A double mutant heat-labile toxin from Escherichia coli, LT (R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun. 2013;81(5):1532–1540.
39. Zhang HX, Qiu YY, Zhao YH et al. Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant. Mol Cell Probes. 2014;28(1):25–30.
40. Anderl F, Gerhard M. Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol. 2014;20(34):11939–11949.
41. Aebischer T, Bumann D, Epple HJ et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21abased Salmonella vaccines. Gut. 2008;57(8):1065–1072.
42. Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology. 2008;135:787–795.
43. Zeng M, Mao XH, Li JX et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(10002):1457–1464.
44. Uspenskiy YP, Baryshnikova NV. Functional dyspepsia and chronic gastritis. Pediatrician. 2018;9(1):77– 83. In Russian.
45. Gurova MM, Uspenskiy YP. Intellectual characteristics of adolescent children with chronic gastroduodenitis. Pediatrician. 2017;8(3):15–22. In Russian.
Review
For citations:
Uspenskiy Yu.P., Gorbacheva I.A., Suvorov A.N., Galagudza M.M., Baryshnikova N.V., Bogdanova S.A. IMMUNOLOGICAL CHANGES IN THE INVASION OF HELICOBACTER PYLORI: PROSPECTS FOR CREATING VACCINES. Translational Medicine. 2018;5(6):31-40. (In Russ.) https://doi.org/10.18705/2311-4495-2018-5-6-31-40
Views:
988
Email this article 